This new, expanded indication supplements the original 2008 FDA approval of FUSILEV. The drug is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma and for diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
Read the news release about the FDA approval of FUSILEV.
Related Articles on Colorectal Cancer:
Protein Biomarker Linked to Better Colorectal Cancer Survival for Obese
Study: Breast, Ovarian Cancer Drug May Have Utility in Treating Colorectal Cancer
Office Desk Jobs Double Colon Cancer Risk
